Fulgent Genetics (NASDAQ:FLGT) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.32) by 96.88 percent. This is a 95.45 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $64.485 million which missed the analyst consensus estimate of $65.363 million by 1.34 percent. This is a 2.54 percent decrease over sales of $66.168 million the same period last year.